Quarterly ResultMay 12, 2026, 07:32 AM
Xilio Therapeutics Advances Pipeline, Extends Cash Runway into Early 2028
AI Summary
Xilio Therapeutics announced significant pipeline progress and business updates, alongside its first quarter 2026 financial results. The company is on track for XTX501's IND submission in mid-2026 and Phase 1 initiation in the second half of 2026, and presented new preclinical data for XTX601. Xilio also achieved a $6.0 million development milestone under its AbbVie collaboration, extending its cash runway into early 2028. For Q1 2026, the company reported $12.6 million in collaboration and license revenue and a net loss of $9.5 million.
Key Highlights
- XTX501 IND submission planned for mid-2026, Phase 1 initiation in H2 2026.
- XTX601 preclinical data presented at AACR, demonstrating tumor-selective activation.
- Achieved $6.0 million development milestone under AbbVie collaboration.
- Cash and cash equivalents were $150.3 million as of March 31, 2026.
- Collaboration and license revenue was $12.6 million for Q1 2026.
- Net loss was $9.5 million for Q1 2026, down from $13.3 million YoY.
- Cash runway extended into early 2028.
- Potential for up to $31.0 million in additional near-term AbbVie milestones.